Tissue Regenix expands further in the US with ‘hybrid’ model

MEDICAL device firm Tissue Regenix has signed a US distribution agreement, expanding its reach in a major market.

The agreement with TRX Wound Care Inc to distribute the firm’s DermaPure product is worth more than £86,000.

This follows the announcement that another two states would be covered in a deal worth more than £384,000.

The firm said that this was indicative of the growing market interest in DermaPure, which has become available to 20.7m Medicare beneficiaries across 30 states in the first six month of 2015, according to the firm.

York-based Tissue Regenix Group chief executive Antony Odell commented:”2015 has been a seminal year for DermaPure® in the United States and this is credit to the hard work being undertaken by our regional team.

“This announcement is another demonstration of the group delivering on its strategy to fully commercialise DermaPure in the United States and highlights the benefits of our hybrid distribution strategy.

“In light of DermaPure’s continued provision of outstanding clinical outcomes, I remain confident in achieving both further coverage by Medicare administrators and entering into additional beneficial distributor agreements.”